EML4 and non-small cell lung carcinoma: For example, the identification of EML4 > ALK gene fusions in non-small cell lung cancer paved the way for the development of ALK inhibitors and recently drugs targeting tumors of any cancer type with gene fusions involving NTRK genes have been approved by the FDA43,44.